Women who have experienced heavy menstrual bleeding since their first period and have indications of a coagulation disorder in their personal or family medical history should undergo testing for such disorders, including von Willebrand’s disease. This recommendation is made by NICE CG44.

Understanding Menorrhagia: Causes and Definition

Menorrhagia is a condition characterized by heavy menstrual bleeding. While it was previously defined as total blood loss exceeding 80 ml per menstrual cycle, the assessment and management of the condition now focuses on the woman’s perception of excessive bleeding and its impact on her quality of life. Dysfunctional uterine bleeding, which occurs in the absence of underlying pathology, is the most common cause of menorrhagia, accounting for about half of all cases. Anovulatory cycles, uterine fibroids, hypothyroidism, pelvic inflammatory disease, and bleeding disorders such as von Willebrand disease are other potential causes of menorrhagia. It is important to note that the use of intrauterine devices, specifically copper coils, may also contribute to heavy menstrual bleeding. However, the intrauterine system (Mirena) is a treatment option for menorrhagia.

Paraneoplastic syndromes are a group of disorders that can occur in patients with certain types of cancer, but are not caused by metastases, infections, metabolic disorders, chemotherapy, or coagulation disorders. These syndromes can present with a variety of symptoms affecting different body systems. Some of these syndromes are specific to certain types of cancer and may be the first sign of the disease. Therefore, if a patient presents with symptoms of a paraneoplastic syndrome, it is important to consider the possibility of an underlying malignancy. While certain paraneoplastic syndromes are associated with specific types of cancer, there can be some overlap.

After giving birth, women need to use contraception only after 21 days.

As the woman in the question is only 14 days post-partum, she does not need emergency contraception. Therefore, the advice to her would be that emergency contraception is not necessary.

After giving birth, women need to use contraception after 21 days. The progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Medications for Glaucoma: Uses and Contraindications

Glaucoma is a condition that can lead to vision loss if left untreated. The primary goal of treatment is to lower intraocular pressure. Here are some common medications used for glaucoma and their uses and contraindications:

1. Latanoprost: This prostaglandin analogue increases scleral permeability to aqueous fluid, reducing intraocular pressure. It is safe to use in asthmatics and is recommended as a first-line medication.

2. Brinzolamide: This carbonic anhydrase inhibitor also lowers intraocular pressure but is not a first-line medication for glaucoma. It is safe to use in those with concurrent asthma.

3. Pilocarpine: This muscarinic receptor agonist improves the flow rate of aqueous humour but is not a first-line medication. It is cautioned against use in asthmatics as it can increase bronchial secretions and airway resistance.

4. Sodium cromoglicate: This mast-cell stabiliser is not usually used in glaucoma but is commonly used in conditions such as allergic rhinitis.

5. Timolol: This beta-receptor antagonist is contraindicated in asthmatics as it can lead to increased airway resistance through bronchospasm.

It is important to consult with a healthcare provider to determine the best medication for individual cases of glaucoma, taking into consideration any contraindications or potential side effects.

Vagal manoeuvres, such as carotid sinus massage or the Valsalva manoeuvre, are the initial treatment for supraventricular tachycardia. Adenosine should only be administered if these manoeuvres are ineffective. According to the ALS guidelines, direct current cardioversion is not recommended for this condition.

Understanding Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a type of tachycardia that originates above the ventricles. It is commonly associated with paroxysmal SVT, which is characterized by sudden onset of a narrow complex tachycardia, usually an atrioventricular nodal re-entry tachycardia (AVNRT). Other causes include atrioventricular re-entry tachycardias (AVRT) and junctional tachycardias.

When it comes to acute management, vagal maneuvers such as the Valsalva maneuver or carotid sinus massage can be used. Intravenous adenosine is also an option, with a rapid IV bolus of 6mg given initially, followed by 12mg and then 18mg if necessary. However, adenosine is contraindicated in asthmatics, and verapamil may be a better option for them. Electrical cardioversion is another option.

To prevent episodes of SVT, beta-blockers can be used. Radio-frequency ablation is also an option. It is important to work with a healthcare provider to determine the best course of treatment for each individual case.

Overall, understanding SVT and its management options can help individuals with this condition better manage their symptoms and improve their quality of life.

Behçet’s disease is a rare autoimmune condition that causes painful recurrent mouth and genital ulcers leading to scarring. Diagnosis is often delayed due to the absence of a definitive diagnostic test. This patient has had a rash associated with Behçet’s disease and an episode of acute red eye, which may have been anterior uveitis, another symptom of the condition. Herpes simplex infection, Crohn’s disease, coeliac disease, and lichen planus are all conditions that can cause similar symptoms but can be ruled out based on the patient’s medical history and physical examination.

Management of Dyspepsia in Primary Care: Guidelines and Recommendations

Dyspepsia is a common complaint in primary care, encompassing a range of symptoms such as epigastric pain, heartburn, acid regurgitation, bloating, nausea, and vomiting. Here are some guidelines and recommendations for managing dyspepsia in primary care:

One-month trial of full-dose PPI: NICE guidelines recommend offering empirical full-dose PPI therapy for 4 weeks to patients with dyspepsia. Helicobacter pylori testing should also be offered, but a 2-week washout PPI-free period is necessary before testing.

Helicobater pylori stool test and routine referral for OGD: In young patients with no risk factors and relatively benign history and physical findings, routine referral for an endoscopy or testing for Barrett’s esophagus is not necessary.

Long-term low-dose PPI: If symptoms recur after initial treatment, offering a PPI at the lowest dose possible to control symptoms would be appropriate. H2 receptor antagonist therapy should be considered if there is an inadequate response to a PPI.

Refer urgently for OGD: Patients presenting with dyspepsia and significant acute GI bleeding should be referred for same-day assessment to a specialist. Other reasons for urgent referral would be the suspicion of malignancy, which in young patients with no red flag symptoms would be unwarranted.

Triple therapy for Helicobacter pylori eradication: Testing for Helicobacter pylori should be offered to patients with dyspepsia after a 2-week washout PPI-free period. It would be inappropriate to initiate triple therapy treatment without a positive test result first.

In summary, dyspepsia in the general population in primary care is defined broadly to include patients with recurrent epigastric pain, heartburn or acid regurgitation, with or without bloating, nausea, or vomiting. Management should follow evidence-based guidelines and recommendations to ensure appropriate and effective treatment.

To detect Down’s syndrome, doctors recommend the combined test which involves measuring the thickness of the nuchal translucency during the 12-week scan, as well as conducting blood tests for B-HCG and PAPP-A. This test can only be done between 11 and 13+6 weeks of pregnancy. If the nuchal translucency is thickened, B-HCG levels are high, and PAPP-A levels are low, there is an increased likelihood of Down’s syndrome. The other options listed are incorrect. If a woman misses the window for the combined test, she may be offered the triple or quadruple test between 15-20 weeks, which includes AFP as a marker for Down’s syndrome. Low levels of AFP indicate a higher risk of Down’s syndrome.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

To prevent angina attacks, the first-line treatment is either a beta-blocker or a calcium channel blocker. If a person experiences chest pain that feels like squeezing during physical activity but goes away with rest, it is likely stable angina. Having high cholesterol levels increases the risk of developing this condition. A normal electrocardiogram (ECG) indicates that there is no ongoing heart attack.

Angina pectoris is a condition that can be managed through various methods, including lifestyle changes, medication, percutaneous coronary intervention, and surgery. In 2011, NICE released guidelines for the management of stable angina. Medication is an important aspect of treatment, and all patients should receive aspirin and a statin unless there are contraindications. Sublingual glyceryl trinitrate can be used to abort angina attacks. The first-line medication should be either a beta-blocker or a calcium channel blocker, depending on the patient’s comorbidities, contraindications, and preferences. If a calcium channel blocker is used as monotherapy, a rate-limiting one such as verapamil or diltiazem should be used. If used in combination with a beta-blocker, a longer-acting dihydropyridine calcium channel blocker should be used. Beta-blockers should not be prescribed concurrently with verapamil due to the risk of complete heart block. If the initial treatment is not effective, medication should be increased to the maximum tolerated dose. If a patient is still symptomatic after monotherapy with a beta-blocker, a calcium channel blocker can be added, and vice versa. If a patient cannot tolerate the addition of a calcium channel blocker or a beta-blocker, other drugs such as long-acting nitrates, ivabradine, nicorandil, or ranolazine can be considered. Nitrate tolerance is a common issue, and patients who take standard-release isosorbide mononitrate should use an asymmetric dosing interval to maintain a daily nitrate-free time of 10-14 hours to minimize the development of nitrate tolerance. This effect is not seen in patients who take once-daily modified-release isosorbide mononitrate. If a patient is taking both a beta-blocker and a calcium-channel blocker, a third drug should only be added while awaiting assessment for PCI or CABG.

Management of Transient Visual Loss and Carotid Artery Stenosis

Transient visual loss can be caused by various factors, including retinal ischemia and emboli from atherosclerotic carotid arteries. In cases where Doppler ultrasound shows 40% stenosis of the internal carotid artery, surgery is not recommended. Instead, best medical treatment should be administered, including control of blood pressure, antiplatelet agents, cholesterol-lowering drugs, and lifestyle advice. Acute treatment with 300 mg aspirin is recommended, followed by high-dose treatment for two weeks before initiating long-term antithrombotic treatment.

Prednisolone is used in the treatment of giant cell arteritis, which can also cause transient visual loss. Diagnosis requires three out of five criteria, including age over 50, new headache, temporal artery abnormality, elevated ESR, and abnormal artery biopsy.

Carotid artery angioplasty may be considered as an alternative to carotid endarterectomy for revascularization in select cases. However, there are concerns regarding stent placement and the risk of stroke. Surgical management is only indicated for carotid artery stenosis over 50%.

Anticoagulation treatment is not routinely used for the treatment of acute stroke. It may be considered for those in atrial fibrillation or at high risk of venous thromboembolism. For patients with a history of transient ischemic attack, high-dose aspirin is recommended for two weeks post-event, followed by long-term secondary prevention with aspirin and modified-release dipyridamole or clopidogrel.

Management of Transient Visual Loss and Carotid Artery Stenosis